References
- Lyon AR, López-Fernánde T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229–4361.
- Mauro C, Capone V, Cocchia R et al. Cardiovascular side effects of anthracyclines and HER2 inhibitors among patients with breast cancer: A multidisciplinary stepwise approach for prevention, early detection, and treatment. J Clin Med 2023; 12: 2121.
- Brown A, Kumar S, Tchounwou PB. Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther 2019; 11.
- Hu Y, Sun B, Zhao B, Mei D, Gu Q, Tian Z. Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature. Medicine (United States) 97 2018.
- V M-M. A case report of cisplatin-induced cardiotoxicity: A side effect to monitor closely. J Heart Health 2017; 3.
- Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270–276.
- Kim KH, Pereira NL. Genetics of cardiomyopathy: Clinical and mechanistic implications for heart failure. Korean Circ J 2021; 51.
- Arbelo E, Protonotarios A, Gimeno JR et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503–3626.
- Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 2019; 140: 31–41.
- Herman DS, Lam L, Taylor MRG et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 366: 619–628.
- Ware JS, Cook SA. Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat Rev Cardiol 2018; 15: 241–252.
- Roberts AM, Ware JS, Herman DS et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med 2015; 7.
- Akinrinade O, Koskenvuo JW, Alastalo TP. Prevalence of titin truncating variants in general population. PLoS One 2015; 10.
- Abu-Rustum NR, Yashar CM, Arend R et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw 2023; 21: 1224–1233.
- Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 2007; 39: 43–50.
- Murata T, Hibasami H, Maekawa S, Tagawa T, Nakashima K. Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int 1990; 20: 949–55.
- Ma H, Jones KR, Guo R, Xu P, Shen Y, Ren J. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 2010; 37: 460–465.
- Rachma B, Savitri M, Sutanto H. Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management. Cancer Pathogenesis and Therapy 2024;
- Bjerring AW, Fosså SD, Haugnes HS et al. The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. Eur Heart J Cardiovasc Imaging 2021; 22: 443–450.
- Altena R, Hummel YM, Nuver J et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011; 22: 2286–2293.
- Alavi M, Webster TJ. Nano liposomal and cubosomal formulations with platinum-based anticancer agents: therapeutic advances and challenges. Nanomedicine (Lond) 2020; 15: 2399–2410.
- Federico C, Sun J, Muz B et al. Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side-effect profile. Int J Radiat Oncol Biol Phys 2021; 109: 1483.